# A Study of TAVO101 in Atopic Dermatitis Patients

> **NCT06176040** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tavotek Biotherapeutics** · enrollment: 20 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** TAVO101

## Key facts

- **NCT ID:** NCT06176040
- **Lead sponsor:** Tavotek Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-15
- **Primary completion:** 2025-03-15
- **Final completion:** 2025-06-15
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176040, "A Study of TAVO101 in Atopic Dermatitis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06176040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*